Skip to main content
Passa alla visualizzazione normale.


Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

  • Authors: Sasso F.C.; Pafundi P.C.; Caturano A.; Galiero R.; Vetrano E.; Nevola R.; Petta S.; Fracanzani A.L.; Coppola C.; Di Marco V.; Solano A.; Lombardi R.; Giordano M.; Craxi A.; Perrella A.; Sardu C.; Marfella R.; Salvatore T.; Adinolfi L.E.; Rinaldi L.
  • Publication year: 2021
  • Type: Articolo in rivista
  • OA Link:


Background and aims: Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive cohort. Methods and results: In this prospective multicenter study, we enrolled HCV patients with overt prediabetes. We compared a subgroup of patients treated with DAAs with untreated prediabetic controls. We recorded all CV events occurred during an overall median follow-up of 24 months (IQR 19–34). 770 HCV positive prediabetic patients were enrolled, 398 untreated controls and 372 DAAs treated patients. Overall, the CV events annual incidence was much higher among prediabetic treated patients (1.77 vs. 0.62, p < 0.001), and HCV clearance demonstrated to significantly reduce CV events (RR: 0.411, 95%CI 0.148–1.143; p < 0.001), with an estimated NNT for one additional patient to benefit of 52.1. Moreover, an independent association between a lower rate of CV events and HCV clearance after DAAs was observed (OR 4.67; 95%CI 0.44–53.95; p = 0.016). Conclusions: HCV eradication by DAAs allows a significant reduction of MACEs in the prediabetic population, and therefore represents a primary objective, regardless of the severity of liver disease and CV risk factors.